ketoconazole has been researched along with estramustine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dunzendorfer, U; Oelschläger, H; Rothley, D | 1 |
| Abi-Rashid, B; Petrylak, DP | 1 |
| Amato, RJ; Ellerhorst, JA; Finn, L; Jackson, A; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Tu, SM | 1 |
| Finn, L; Kamoi, K; Logothetis, CJ; Pettaway, CA; Pisters, LL; Slaton, J; Troncoso, P | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| George, DJ; Gilligan, TD; Hagmann, E; Jacobson, JO; Kantoff, PW; Kaufman, DS; Manola, J; Oh, WK; Smith, MR | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D | 1 |
| Brown, MA; Do, KA; Logothetis, CJ; Millikan, RE; Moomey, B; Pagliaro, LC; Wen, S | 1 |
| Amato, RJ; Henary, H; Hernandez-McClain, J | 1 |
2 review(s) available for ketoconazole and estramustine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapy for hormone-resistant prostate cancer: no longer a myth.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Humans; Ketoconazole; Male; Prostatic Neoplasms; Suramin; Treatment Outcome | 1996 |
7 trial(s) available for ketoconazole and estramustine
| Article | Year |
|---|---|
Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Confidence Intervals; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Humans; Hydrocortisone; Ketoconazole; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Survival Analysis; Vinblastine | 1997 |
Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.
Topics: Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Estramustine; Feasibility Studies; Follow-Up Studies; Humans; Ketoconazole; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Ultrasonography; Vinblastine | 2000 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2005 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Estramustine; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Vinblastine | 2008 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Estramustine; Humans; Ketoconazole; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Strontium Radioisotopes; Survival Rate; Treatment Outcome | 2008 |
5 other study(ies) available for ketoconazole and estramustine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
[Drug therapy of metastasizing prostate carcinoma with special reference to the bioavailability of fosfestrol after oral administration].
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Biotransformation; Carcinoma; Chemical Phenomena; Chemistry; Diethylstilbestrol; Estramustine; Estrogens; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Protein Binding | 1988 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |